Project IMMUNED - CA209-184

Basic data

Title:
IMMUNED - CA209-184
Duration:
01/04/2015 to 30/06/2021
Abstract / short description:
A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease - IMMUNED
Keywords:
immunotherapy
Immuntherapie
Nivolumab
Ipilimumab
melanoma
Melanom
skin cancer
Hautkrebs

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Duisburg, Nordrhein-Westfalen, Germany
Help

will be deleted permanently. This cannot be undone.